Translational Cancer Research

What is translational cancer research?

Translational cancer research, also termed ‘bench-to-bedside', aims to efficiently translate research findings from the laboratory into clinical practice for rapid impact on cancer treatment and outcomes.

The Cancer Institute NSW currently supports translational cancer research through Translational Program Grants, an Accelerated Translational Research Grant, and Translational Capacity Building Grants. These large grants support multi-disciplinary research teams to rapidly translate cancer research into clinical programs and policy.

Translational cancer research investment since 2004

funded

grants funded

universities and
research institutions

Changing the face of liver cancer in NSW

Supported by a new, landmark $4 million grant from the Cancer Institute NSW, the Accelerated Translational Research in PRImary Liver Cancer (APRICA) program will bring together researchers, clinicians and experts across the state to improve liver cancer outcomes.

Program-lead Professor Jacob George, a renowned liver specialist and liver research scientist based at Westmead Hospital and The Westmead Institute for Medical Research, hopes the funding will change the face of liver cancer in NSW and beyond.

“It’s an exceptionally unique opportunity... a big picture approach to say ‘Let’s look at the whole gamut of what we need to do’,” Professor George says.